Brett Staahl and Benjamin Oakes
October 6, 2020 10:38 AM EDTUpdated October 8, 04:05 PM
People
Startups

The lat­est Jen­nifer Doud­na start­up launch­es with a Bio­gen part­ner­ship and eyes on big tar­gets few CRISPR com­pa­nies have chased

Jason Mast

Editor

Three years ago, Jen­nifer Doud­na gath­ered with two post­docs and a fel­low bio­chemist around a cir­cu­lar ta­ble on the sec­ond floor of UC Berke­ly’s En­er­gy …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Sanofi in­tro­duces new 340B pay­ment mod­el — re­port

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times